Eli Lilly and Co (NYSE:LLY) – Stock analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for Eli Lilly and in a note issued to investors on Friday, April 13th. Jefferies Group analyst I. Hilliker expects that the company will earn $1.11 per share for the quarter. Jefferies Group has a “Buy” rating and a $90.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2019 earnings at $5.26 EPS, FY2020 earnings at $6.13 EPS and FY2022 earnings at $7.77 EPS.
A number of other equities research analysts have also commented on the company. BMO Capital Markets upgraded Eli Lilly and from an “underperform” rating to a “market perform” rating and increased their price target for the stock from $74.00 to $79.00 in a research report on Friday. They noted that the move was a valuation call. JPMorgan Chase set a $105.00 price target on Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Zacks Investment Research lowered Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Tuesday, March 27th. Credit Suisse Group restated a “hold” rating and set a $80.00 price target on shares of Eli Lilly and in a research report on Friday, February 2nd. Finally, TheStreet lowered Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $93.16.
LLY stock opened at $79.72 on Monday. Eli Lilly and has a 1-year low of $73.69 and a 1-year high of $89.09. The company has a market capitalization of $86,869.96, a PE ratio of 18.63, a P/E/G ratio of 1.48 and a beta of 0.26. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. During the same period in the prior year, the company posted $0.95 EPS. The company’s revenue was up 7.0% compared to the same quarter last year.
Large investors have recently bought and sold shares of the business. Chevy Chase Trust Holdings Inc. lifted its holdings in Eli Lilly and by 1.0% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 851,985 shares of the company’s stock worth $72,879,000 after buying an additional 8,328 shares in the last quarter. Exane Derivatives lifted its stake in shares of Eli Lilly and by 2,838.2% in the 4th quarter. Exane Derivatives now owns 18,687 shares of the company’s stock valued at $1,578,000 after purchasing an additional 18,051 shares during the period. Valeo Financial Advisors LLC acquired a new position in shares of Eli Lilly and in the 3rd quarter valued at $3,463,000. OppenheimerFunds Inc. lifted its stake in shares of Eli Lilly and by 8.1% in the 4th quarter. OppenheimerFunds Inc. now owns 43,699 shares of the company’s stock valued at $3,690,000 after purchasing an additional 3,257 shares during the period. Finally, Lazard Asset Management LLC lifted its stake in shares of Eli Lilly and by 0.8% in the 4th quarter. Lazard Asset Management LLC now owns 826,865 shares of the company’s stock valued at $69,835,000 after purchasing an additional 6,437 shares during the period. 77.66% of the stock is currently owned by hedge funds and other institutional investors.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,261 shares of company stock worth $1,225,085. Company insiders own 0.11% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Jefferies Group Comments on Eli Lilly and Co’s Q1 2018 Earnings (LLY)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/16/jefferies-group-comments-on-eli-lilly-and-cos-q1-2018-earnings-lly.html.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.